Ann Surg Treat Res.  2024 Oct;107(4):187-194. 10.4174/astr.2024.107.4.187.

Early stage adrenocortical carcinoma—what contributes to poor prognosis after adrenalectomy? A retrospective cohort study

• Kwon D
• Rah CS
• Kim BC
• Pak SJ
• Cho JW
• Kim WW
• Lee Ym
• Lee JL
• Song DE
• Chung KW
• Sung TY

• KMID: 2560003
• DOI: http://doi.org/10.4174/astr.2024.107.4.187

Abstract

Purpose
Adrenocortical carcinoma (ACC) is a rare primary carcinoma originating in the adrenal gland with a poor prognosis and a high recurrence rate. This study evaluated the risk factors associated with recurrence in patients with early stage ACC after curative surgical resection.
Methods
The present study retrospectively evaluated the risk factors for recurrence in 38 patients with stages 1 and 2 ACC who underwent curative resection between 1995 and 2020.
Results
Recurrence was observed in 21 patients (55.3%), with no significant difference between stages 1 and 2 ACC (P = 0.640). The overall recurrence rate was higher in patients who underwent minimally invasive surgery than open adrenalectomy (71.4% vs. 51.6%). Of the 33 patients with gross tumor margins negative for malignancy, 16 (48.5%) experienced tumor recurrence, and all 5 patients with positive and unknown gross resection margins had recurrence. Recurrences were observed in 14 of the 30 patients (46.7%) negative for pathologic resection margins, 6 of the 7 patients (85.7%) with pathologically indeterminate margins, and 1 patient with pathologically positive margins.
Conclusion
The recurrence rates are high even in patients with early stage ACC, being higher in patients who undergo minimally invasive surgery than open adrenalectomy. Obtaining clear resection margins during surgery may reduce tumor recurrence; however, gross or pathologic margin safety was not a secure factor in preventing recurrence. None of the factors analyzed was a definitive predictor of poor prognosis.

Keyword

Adrenocortical carcinoma; Adrenalectomy; Early stage; Recurrence

Figure

• 

  Fig. 1 Study population.

• 

  Fig. 2 Kaplan-Meier analysis of disease-free survival rates in patients with early stage adrenocortical carcinoma.

Reference

1. Chandrasekar T, Goldberg H, Klaassen Z, Wallis CJ, Woon DT, Herrera-Caceres JO, et al. The who, when, and why of primary adrenal malignancies: insights into the epidemiology of a rare clinical entity. Cancer. 2019; 125:1050–1059. PMID: 30561782.

2. Kebebew E, Reiff E, Duh QY, Clark OH, McMillan A. Extent of disease at presentat ion and outcome for adrenocortical carcinoma: have we made progress? World J Surg. 2006; 30:872–878. PMID: 16680602.

3. Søreide JA, Brabrand K, Thoresen SO. Adrenal cortical carcinoma in Norway, 1970-1984. World J Surg. 1992; 16:663–668. PMID: 1413834.

4. Kerkhofs TM, Verhoeven RH, Van der Zwan JM, Dieleman J, Kerstens MN, Links TP, et al. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer. 2013; 49:2579–2586. PMID: 23561851.

5. Sharma E, Dahal S, Sharma P, Bhandari A, Gupta V, Amgai B, et al. The characteristics and trends in adrenocortical carcinoma: a United States population based study. J Clin Med Res. 2018; 10:636–640. PMID: 29977421.

6. Rah CS, Cho JW, Kim WW, Lee YM, Chung KW, Koh JM, et al. Change of treatment modality and outcomes of adrenocortical carcinoma: a retrospective review of single tertiary center experience over 24 years. Gland Surg. 2022; 11:1615–1627. PMID: 36353581.

7. Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Alì A, et al. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the Italian Society of Endocrinology. J Clin Endocrinol Metab. 2000; 85:637–644. PMID: 10690869.

8. Boland GW, Lee MJ, Gazelle GS, Halpern EF, McNicholas MM, Mueller PR. Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature. AJR Am J Roentgenol. 1998; 171:201–204. PMID: 9648789.

9. Johnson PT, Horton KM, Fishman EK. Adrenal mass imaging with multidetector CT: pathologic conditions, pearls, and pitfalls. Radiographics. 2009; 29:1333–1351. PMID: 19755599.

10. Allolio B, Fassnacht M. Clinical review: Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab. 2006; 91:2027–2037. PMID: 16551738.

11. Phan AT, Grogan RH, Rohren E, Perrier ND. Adrenal cortical carcinoma. Amin MB, Edge SB, Greene FL, Cherian KR, Compton CC, Schilsky E, editors. AJCC Cancer Staging Manual. 8th ed. Springer;2016. p. 919–926.

12. Icard P, Goudet P, Charpenay C, Andreassian B, Carnaille B, Chapuis Y, et al. Adrenocortical carcinomas: surgical trends and results of a 253-patient series from the French Association of Endocrine Surgeons study group. World J Surg. 2001; 25:891–897. PMID: 11572030.

13. Kendrick ML, Lloyd R, Erickson L, Farley DR, Grant CS, Thompson GB, et al. Adrenocortical carcinoma: surgical progress or status quo? Arch Surg. 2001; 136:543–549. PMID: 11343545.

14. Bilimoria KY, Shen WT, Elaraj D, Bentrem DJ, Winchester DJ, Kebebew E, et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer. 2008; 113:3130–3136. PMID: 18973179.

15. Puglisi S, Calabrese A, Basile V, Pia A, Reimondo G, Perotti P, et al. New perspectives for mitotane treatment of adrenocortical carcinoma. Best Pract Res Clin Endocrinol Metab. 2020; 34:101415. PMID: 32179008.

16. Grubbs EG, Callender GG, Xing Y, Perrier ND, Evans DB, Phan AT, et al. Recurrence of adrenal cortical carcinoma following resection: surgery alone can achieve results equal to surgery plus mitotane. Ann Surg Oncol. 2010; 17:263–270.

17. Corso CR, Acco A, Bach C, Bonatto SJ, de Figueiredo BC, de Souza LM. Pharmacological profile and effects of mitotane in adrenocortical carcinoma. Br J Clin Pharmacol. 2021; 87:2698–2710. PMID: 33382119.

18. Buller DM, Hennessey AM, Ristau BT. Open versus minimally invasive surgery for suspected adrenocortical carcinoma. Transl Androl Urol. 2021; 10:2246–2263. PMID: 34159107.

19. Weiss LM, Medeiros LJ, Vickery AL Jr. Pathologic features of prognostic significance in adrenocortical carcinoma. Am J Surg Pathol. 1989; 13:202–206. PMID: 2919718.

20. Beuschlein F, Weigel J, Saeger W, Kroiss M, Wild V, Daffara F, et al. Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. J Clin Endocrinol Metab. 2015; 100:841–849. PMID: 25559399.